News

The E.coli|360-HCP ELISA allows sponsors and biotech companies to postpone the development of a cost-intensive specific HCP assay until a more informed decision on the success of a

The clinical trial application for the varicella vaccine was officially accepted by the China Food and Drug Administration (CFDA) in January 2013. In preparation to begin human clinical

The systems are synergistic, complementary and work well together. Daylight IQ will now pre-populate select INTERACT forms based on existing nursing documentation. This exchange of data positively impacts

The AAC reviewed safety and efficacy data from the pivotal Phase III combination therapy programme trials, representing the largest clinical trial data set of gout patients treated with

The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. Janssen has optioned 11 programs out of a total of 20 programs under the

The technology provides targeted release of gastric acid- and heat-sensitive active ingredients to the upper gastrointestinal tract. It allows oral delivery of several compounds, including vaccines, proteins and

ondelis is approved for patients with two forms of STS, liposarcoma or leiomyosarcoma, who had earlier received chemotherapy that contained anthracycline. While it is approved for both leiomyosarcoma

The company received a complete response letter, which the FDA sends to a company to inform that the marketing application will not be approved in its existing form.

Imlygic, also known as talimogene laherparepvec (T-Vec), is recommended to treat adults with unresectable melanoma that is regionally or distantly metastatic with no bone, brain, lung or other